To determine whether stereotactic core biopsy (SCNB) is the diagnostic method of choice for all mammographic abnormalities requiring tissue sampling.
Objective
To determine whether stereotactic core biopsy (SCNB) is the diagnostic method of choice for all mammographic abnormalities requiring tissue sampling.
Summary Background Data
Stereotactic core needle biopsy decreases the cost of diagnosis, but its impact on the number of surgical procedures needed to complete local therapy has not been studied in a large, unselected patient population.
Methods
A total of 1,852 mammographic abnormalities in 1,550 consecutive patients were prospectively categorized for level of cancer risk and underwent SCNB or diagnostic needle localization and surgical excision. Diagnosis, type of cancer surgery, and number of surgical procedures to complete local therapy were obtained from surgical and pathology databases.
Results
The malignancy rate was 24%. Surgical biopsy patients were older, more likely to have cancer, and more likely to be treated with breast-conserving therapy than those in the SCNB group. For all types of lesions, regardless of degree of suspicion, patients diagnosed by SCNB were almost three times more likely to have one surgical procedure. However, for patients treated with lumpectomy alone, the number of surgical procedures and the rate of negative margins did not differ between groups.
Conclusions
Stereotactic core needle biopsy is the diagnostic procedure of choice for most mammographic abnormalities. However, for patients undergoing lumpectomy without axillary surgery, it is an extra invasive procedure that does not facilitate obtaining negative margins.
Stereotactic core needle biopsy (SCNB) has been widely accepted as an alternative to wire localization and surgical excision of nonpalpable breast abnormalities. For the woman with a benign breast lesion, the elimination of a surgical procedure, with its associated complications and cost, is a clear benefit of this approach. For the woman with carcinoma, who will require a surgical procedure for therapy, the benefit of an initial SCNB varies, depending on how accurately the procedure characterizes the malignant lesion and allows definitive therapy with a single surgical procedure. The use of SCNB clearly saves money when only the cost of diagnosis is considered, 1,2 although cost savings vary with the type of lesion being sampled. 2 Few studies have examined the relative benefits of SCNB and surgical biopsy to the completion of local therapy, and studies that have used this end point consist of relatively few, highly selected patients, [3] [4] [5] making them unlikely to have the power to identify a subgroup of patients who do not benefit from SCNB. This prospective study was undertaken to determine whether SCNB is the diagnostic procedure of choice for all mammographic abnormalities deemed suspicious enough to require histologic sampling. The number of surgical procedures to the completion of local therapy was the end point chosen because the need for multiple surgical procedures is a cause of physical, cosmetic, and psychological problems for the patient, as well as the major determinant of cost.
PATIENTS AND METHODS
Between September 1, 1996, and August 31, 1998, 1,550 consecutive patients with 1,852 nonpalpable, mammographically detected abnormalities seen at the Lynn Sage Comprehensive Breast Center participated in this study. Patients were selected for an image-guided core biopsy or surgical biopsy in a nonrandomized fashion after completion of the diagnostic imaging workup. Treatment selection reflected the radiologist's assessment of the suitability of the patient for image-guided breast biopsy, as well as the preference of the patient and the referring physician. In the absence of medical contraindications to image-guided breast biopsy, no standard criteria were used to select the type of biopsy procedure.
At the time of biopsy, the attending radiologist recorded the type of mammographic abnormality (i.e., mass, calcification, or architectural distortion). All lesions were BI-RADS category 4 or 5, 6 but because to the widely varying levels of breast cancer risk encompassed by BI-RADS category 4, this group was subdivided into four risk categories (Table 1) to allow a more precise estimation of risk. All lesions were assigned a risk score of 1 to 5. In patients with multiple lesions, each lesion was given an individual risk score.
Information regarding patient age, tumor histology, type of surgical procedure, and the number of surgical procedures to complete local therapy was obtained from the breast cancer database. All pathology records for each patient within 1 year of the time of breast cancer diagnosis were reviewed to ensure complete recording of the number of surgical procedures. Patients who underwent biopsies at the Lynn Sage Breast Center but had definitive local therapy elsewhere were excluded from analysis.
Statistical comparisons between groups were performed using a two-tailed Student t test and chi-square analysis.
RESULTS
The characteristics of patients in the surgical biopsy group and the core biopsy group are compared in Table 2 .
The indication for biopsy was a mass in 934 patients, calcifications in 805 patients, and architectural distortion in 113 patients. The incidence of malignancy in these groups was 23.7%, 19.4%, and 28.3%, respectively. There were 151 cases of intraductal carcinoma and 298 invasive malignancies. Patients in the surgical biopsy group has a mean age of 55.2 years versus 52.7 years for their counterparts in the core biopsy group (P ϭ .05). Lesions selected for surgical biopsy were more likely to be malignant than those selected for core biopsy (26.1% vs. 20.4%; P ϭ .01). Cancer patients in the surgical biopsy group were significantly more likely than those in the core biopsy group to be treated with breast-conserving therapy (71.1% vs. 55.4%; P ϭ .002), reflecting the preferential use of core biopsy for diffuse abnormalities in our practice. The classification of degree of suspicion of the 1,852 abnormalities in the study is shown in Table 3 . Lesions thought to have a greater than 90% probability of being malignant (BI-RADS 5) accounted for only 6.4% of the abnormalities in this study and were evenly distributed between the surgical biopsy and core biopsy groups. Lesions with the lowest degree of suspicion were also relatively infrequent, accounting for 14.2% of the cases in this study. The incidence of malignancy was 6.1% for category 1 lesions, 5.6% for category 2, 18.5% for category 3, 61% for category 4, and 82.2% for category 5.
In 33% of the 142 patients with cancer undergoing surgical biopsy, the diagnostic biopsy served as the definitive surgical therapy. In contrast, 84% of the 267 patients with cancer initially diagnosed by core biopsy required only a single surgical procedure to complete local therapy, and this difference was highly significant (P Ͻ .0001). The proportion of patients having only one surgical procedure was examined by both lesion type ( Fig. 1 ) and type of local therapy (Fig. 2) . For all types of lesions, patients undergoing core biopsy were more likely than those having a surgical biopsy to undergo a single surgical procedure. Architectural distortion lesions had the smallest differences in rates of single procedures, 25% (71% vs. 46%, P ϭ .001). For the subset of highly suspicious lesions (category of suspicion 4 and 5), including both masses and calcifications, patients diagnosed with core biopsy were more likely to undergo a single surgical procedure (83% vs. 45%, P Ͻ .001; Fig. 3 ). We also evaluated the frequency of single procedures by the type of definitive surgical procedure. All patients diagnosed with a surgical biopsy who underwent a mastectomy required a second surgical procedure because frozen section at the time of surgical biopsy was not used. Twelve percent of patients diagnosed by core biopsy who underwent mastectomy also required a second surgical procedure. In all of these patients, the additional surgery was an axillary dissection necessitated by the finding of invasive carcinoma in the mastectomy specimen that was not identified by the core biopsy. A smaller advantage for core biopsy was evident in patients undergoing breast-conserving therapy, with 85% of those diagnosed by core biopsy having a single surgery versus 47% of those diagnosed surgically. For the subset of 169 patients treated by lumpectomy alone, there was no advantage observed for a core diagnosis, with 73% of patients diagnosed by surgical biopsy and 78% of those diagnosed by core biopsy having a single surgical procedure.
In this study, of the 90 lesions diagnosed as intraductal carcinoma by core biopsy, 13 were found to have an invasive component after definitive surgical excision compared with 4 of 61 cases diagnosed as intraductal carcinoma with a surgical biopsy. A total of 15.7% of patients diagnosed by core biopsy required additional surgery after an attempt at definitive local therapy. In most patients (80.7%), this was due to the need to reexcise a positive margin, but in 19.2% of patients it was secondary to the need for axillary dissection. In patients initially diagnosed surgically, further surgery after definitive local therapy (i.e., a third operation) was necessary in only 2.1% of patients (P ϭ .0001 vs. core biopsy group). In all three patients positive margins were present, and one patient also required axillary dissection.
DISCUSSION
This is the first large prospective study comparing the results of core biopsy with surgical biopsy for a spectrum of mammographic abnormalities classified according to both degree of suspicion and type of local therapy. Whereas previous studies comparing biopsy techniques to an end point of breast cancer diagnosis have suggested that SCNB is the preferred option because of lower diagnostic costs, these studies have not considered the completion of surgical therapy as the relevant time horizon. We have shown that the benefits of core biopsy depend on the type of definitive local therapy undertaken. In patients who require mastectomy, core biopsy clearly decreases the number of surgical procedures needed. It has the added advantage of avoiding an incision on the breast that may be difficult to incorporate in a mastectomy incision or may compromise the cosmetic outcome of immediate breast reconstruction. However, few patients with early-stage, mammographically detected breast carcinoma have medical indications for mastectomy. 7 A more relevant question for practice today is the benefit of core biopsy in patients undergoing breast-conserving surgery. It is claimed that core biopsy, by establishing a preoperative cancer diagnosis, allows the surgeon to perform a "better" lumpectomy. Our results do not substantiate this contention. In patients undergoing lumpectomy alone, 73% of those diagnosed surgically and 77.8% of those diagnosed with core biopsy had a single surgical procedure. A similar experience was reported by Liberman et al, 3 where no benefit for a core diagnosis in obtaining negative surgical margins was identified. In contrast, other studies have reported that negative margins are more likely to be obtained if SCNB is used to obtain a diagnosis of carcinoma before attempting surgery. 4, 5 However, in the study by Whitten et al, 5 a preoperative cancer diagnosis by SCNB was associated with the removal of twice the volume of breast tissue as was resected with a diagnostic surgical biopsy (106 vs. 52 cm 3 , P Ͻ .0001), although tumor size was not significantly different between groups. In a study of 217 lumpectomies for mammographic abnormalities, we have confirmed that after adjusting for the type of mammographic abnormality and surgeon experience, patients diagnosed by core biopsy have significantly more breast tissue removed than those undergoing an initial surgical excision. 8 Because the excision of large amounts of breast tissue has clearly been shown to correlate with poor cosmetic outcome after breastconserving surgery, 9 -11 the performance of large resections after SCNB to ensure negative margins with a single surgical procedure does not seem to be in the best interest of the patient.
Our results suggest that needle localization may be preferred over SCNB as a diagnostic test in patients treated with lumpectomy alone who do not require axillary surgery. In this study, patients who did not undergo axillary dissection included those with intraductal carcinoma, microinvasive carcinoma (defined as a single focus of invasion within 2 mm of the basement membrane), or pure tubular carcinoma less than 1 cm in size. In addition, older patients in whom the findings of axillary dissection would not change the approach to adjuvant systemic therapy and who were at low risk for nodal disease on the basis of tumor size did not undergo axillary dissection. Although many of the patients with invasive carcinoma would undergo lymphatic mapping and sentinel lymph node biopsy today, the extremely low risk of nodal metastases in small intraductal carcinomas does not justify routine nodal sampling by dissection or sentinel node biopsy. Approximately 90% of intraductal carcinomas present as microcalcifications without an associated mass lesion, 12 and the risk of invasion in calcification lesions is known to increase with increasing lesion size. 13 Consequently, we suggest that needle localization might be the preferred initial diagnostic test for women with highly suspicious (BI-RADS 5) clustered calcifications suitable for treatment with breast-conserving therapy. Johnson et al, 14 in a study of 50 patients with suspicious microcalcifications, also found that the total number of procedures per patient was decreased with an initial surgical biopsy, as were total costs and the time to definitive local therapy.
14 For this group of patients, the initial diagnostic surgical excision serves as the definitive lumpectomy when negative margins are obtained. This approach would spare patients the need for a purely diagnostic core biopsy, and may reduce the risk of missed carcinomas because the core technique has been shown to be less accurate for the diagnosis of calcifications than it is for mass lesions. 15, 16 For most patients who will undergo axillary surgery or mastectomy, the use of SCNB reduces the number of surgical procedures necessary to complete the surgical treatment of breast cancer.
